e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
COPD: new markers of diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Differences in the polarization of the inflammatory response of patients with chronic obstructive pulmonary disease (COPD) secondary to smoking and to biomass smoke exposure
M. I. Vargas-Rojas, H. Solleiro-Villavicencio, A. Ramírez-Venegas, M. Velázquez-Uncal, R. Quintana, R. Sansores-Martínez (Mexico, Mexico)
Source:
Annual Congress 2013 –COPD: new markers of diseases
Session:
COPD: new markers of diseases
Session type:
Thematic Poster Session
Number:
595
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. I. Vargas-Rojas, H. Solleiro-Villavicencio, A. Ramírez-Venegas, M. Velázquez-Uncal, R. Quintana, R. Sansores-Martínez (Mexico, Mexico). Differences in the polarization of the inflammatory response of patients with chronic obstructive pulmonary disease (COPD) secondary to smoking and to biomass smoke exposure. Eur Respir J 2013; 42: Suppl. 57, 595
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Definition and history of sarcoidosis
Related content which might interest you:
Local and systemic inflammation in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
Comparison of the effects of smoking and biomass exposure in chronic obstructive pulmonary disease
Source: International Congress 2016 – Smoking-related diseases
Year: 2016
Identification of oxidative stress markers and their association with inflammation in smokers and early chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
The systemic inflammation and factors of coagulation in patients with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – COPD markers
Year: 2014
Dynamics of sputum antimicrobial peptide levels in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance
Year: 2015
Influence of systemic inflammation and hypoxaemia on bone metabolism in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Airway inflammation persists after smoking cessation in chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 249s
Year: 2001
Pulmonary function response in smokers and patients with chronic obstructive lung disease (COPD) following exposure to concentrated fine (PM
2.5
) particles
Source: Annual Congress 2009 - Indoor and outdoor air pollution
Year: 2009
Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
COPD, an inflammatory systemic disease. Inflammatory parameters in a group of COPD patients
Source: International Congress 2014 – Lung function, COPD and inflammation
Year: 2014
Evasion of COPD in smokers: at what price?
Source: Eur Respir J 2012; 39: 1298-1303
Year: 2012
The role smoking in development of dust-indusde chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 608s
Year: 2004
Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis
Source: Eur Respir J 2007; 30: 467-471
Year: 2007
Inflammation in COPD: a link to systemic comorbidities
Source: Eur Respir Rev 2007; 16: 91-97
Year: 2007
Tobacco use in relation to COPD and asthma
Source: Eur Respir J 2007; 29: 438-445
Year: 2007
Association between adipokines, inflammatory markers and systemic manifestations in chronic obstructive pulmonary disease (COPD) patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
Increased heart rate modulation, sympathetic dominance and systemic inflammation in chronic obstructive pulmonary disease
Source: International Congress 2014 – Markers
Year: 2014
Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease?
Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease
Year: 2007
Expression of MIC-A in bronchial epithelium associates with cigarette smoking: a sign of induced autoimmune mechanisms?
Source: Annual Congress 2005 - Lung structure: current concepts
Year: 2005
Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity
Source: Annual Congress 2013 –COPD: markers and inflammation
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept